| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -40,597 |
| Stock-based compensation expense | 1,660 |
| Accretion of discount on short-term investments | 1,184 |
| Depreciation and amortization | 1,063 |
| Change in fair value of convertible preferred stock forward | 8,928 |
| Prepaid expenses and other assets | 1,998 |
| Accounts payable | -4,688 |
| Accrued liabilities | -1,479 |
| Operating lease liabilities | -591 |
| Deferred revenue | -3,000 |
| Net cash used in operating activities | -59,742 |
| Purchases of short-term investments | 38,775 |
| Maturities of short-term investments | 46,500 |
| Purchase of property and equipment | 131 |
| Net cash provided by investing activities | 7,594 |
| Proceeds from issuance of convertible preferred stock, net of issuance costs | 65,228 |
| Proceeds from exercise of stock options | 6 |
| Payment of deferred offering costs | 874 |
| Principal payments of finance lease liability | 287 |
| Principal payments of financing obligation | 158 |
| Net cash provided by (used in) financing activities | 63,915 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 11,767 |
| Cash and cash equivalents at beginning of period | 16,463 |
| Cash and cash equivalents at end of period | 28,230 |
Evommune, Inc. (EVMN)
Evommune, Inc. (EVMN)